Bicycle Therapeutics PLC (BCYC)
23.46
+0.75
(+3.30%)
USD |
NASDAQ |
Nov 04, 16:00
23.50
+0.04
(+0.15%)
After-Hours: 20:00
Bicycle Therapeutics Research and Development Expense (Annual): 156.50M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 156.50M |
| December 31, 2022 | 81.61M |
| December 31, 2021 | 44.88M |
| December 31, 2020 | 33.15M |
| Date | Value |
|---|---|
| December 31, 2019 | 25.54M |
| December 31, 2018 | 20.76M |
| December 31, 2017 | 11.87M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
25.54M
Minimum
2019
156.50M
Maximum
2023
68.33M
Average
44.88M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Adaptimmune Therapeutics PLC | 126.51M |
| NuCana PLC | 31.19M |
| TC BioPharm (Holdings) PLC | 9.670M |
| Autolus Therapeutics PLC | 130.48M |
| Mereo BioPharma Group PLC | 17.42M |